title: Survival outcomes of secondary cancers in patients with Waldenström macroglobulinemia: An analysis of the SEER database.
abstract: We hypothesized that survival outcomes of WM patients who develop SM is distinct from the general population of individuals who develop those same malignancies. Using the SEER-18 data (2000-2011), we identified patients with cancers of the breast, prostate, lung, colorectum, bladder, melanoma, non-Hodgkin lymphoma (NHL), and acute leukemia, and compared their outcomes according to having antecedent WM or not. The outcome of interest was overall survival (OS), which was analyzed in proportional-hazard models adjusted for age, sex, race, and stage. We found that patients with WM who developed SM were older than population controls with those same cancers. In the multivariate analysis, WM cases with colorectal cancer (HR 1.97; P < 0.001), melanoma (HR 2.63; P < 0.001) and NHL (HR = 1.35; P = 0.02) had worse OS than controls with those respective cancers. WM patients with diffuse large B-cell lymphoma also had worse OS (HR = 1.86; P = 0.008). The utilization of surgery and radiation was similar between WM cases and controls, except lower rates of prostatectomy and melanoma surgery among WM patients. The survival of WM patients with colorectal cancer, melanoma, and NHL is worse than among general population controls, arguing in favor of age-appropriate cancer screening.
authors.affiliation: Bing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Boston, Massachusetts.|Harvard Medical School, Boston, Massachusetts.
authors.forename: Jorge J
authors.initials: JJ
authors.lastname: Castillo
authors.affiliation: Division of Hematology and Oncology, Memorial Hospital of Rhode Island, the Warren Alpert Medical School of Brown University, Pawtucket, Rhode Island.
authors.forename: Adam J
authors.initials: AJ
authors.lastname: Olszewski
authors.affiliation: Bing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Boston, Massachusetts.
authors.forename: Sandra
authors.initials: S
authors.lastname: Kanan
authors.affiliation: Bing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Boston, Massachusetts.
authors.forename: Kirsten
authors.initials: K
authors.lastname: Meid
authors.affiliation: Bing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Boston, Massachusetts.
authors.forename: Zachary R
authors.initials: ZR
authors.lastname: Hunter
authors.affiliation: Bing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Boston, Massachusetts.|Harvard Medical School, Boston, Massachusetts.
authors.forename: Steven P
authors.initials: SP
authors.lastname: Treon
mesh_terms: D000367:Age Factors; D000368:Aged; D001943:Breast Neoplasms / Q000175:diagnosis / Q000401:mortality* / Q000473:pathology; D015331:Cohort Studies; D015179:Colorectal Neoplasms / Q000175:diagnosis / Q000401:mortality* / Q000473:pathology; D055088:Early Detection of Cancer; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000175:diagnosis / Q000401:mortality* / Q000473:pathology; D008228:Lymphoma, Non-Hodgkin / Q000175:diagnosis / Q000401:mortality* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D016609:Neoplasms, Second Primary / Q000175:diagnosis / Q000401:mortality* / Q000473:pathology; D011379:Prognosis; D016016:Proportional Hazards Models; D011471:Prostatic Neoplasms / Q000175:diagnosis / Q000401:mortality* / Q000473:pathology; D018426:SEER Program; D012737:Sex Factors; D012878:Skin Neoplasms / Q000175:diagnosis / Q000401:mortality* / Q000473:pathology; D016019:Survival Analysis; D001749:Urinary Bladder Neoplasms / Q000175:diagnosis / Q000401:mortality* / Q000473:pathology; D008258:Waldenstrom Macroglobulinemia / Q000175:diagnosis / Q000401:mortality* / Q000473:pathology